Structural and functional evolution of IL-1 targeting: From systemic neutralization to bioengineered nanotherapies

Area of Science:

• Immunology
• Biotechnology
• Drug Development

Background:

• The Interleukin-1 (IL-1) superfamily plays a crucial role in inflammatory responses.
• Current monoclonal antibodies targeting IL-1α and IL-1β are effective but face challenges like poor tissue penetration and systemic immunosuppression risks.

Purpose of the Study:

• To review the evolution of IL-1 therapeutics.
• To examine barriers to conventional antibody efficacy in specific microenvironments.
• To highlight emerging bioengineering strategies for targeted immunomodulation.

Main Methods:

• Review of structural and functional evolution of IL-1 therapeutics.
• Analysis of biophysical barriers affecting immunoglobulin tissue penetration.
• Discussion of novel approaches including dual-blockade bispecifics, combinatorial immunotherapies, single-domain antibodies (nanobodies, VNARs), stimuli-responsive hydrogels, and theranostic nanocarriers.

Main Results:

• Conventional antibodies have limitations in penetrating necrotic and fibrotic tissues.
• Emerging strategies like bispecific antibodies and nanobodies show promise for improved targeting.
• Integration with advanced delivery systems (hydrogels, nanocarriers) enables precision, tissue-specific immunomodulation.

Conclusions:

• A paradigm shift is occurring from broad systemic blockade to precise, tissue-specific immunomodulation for IL-1 superfamily targets.
• Bioengineering, particularly with single-domain antibodies and advanced carriers, is key to overcoming current therapeutic limitations.
• Future IL-1 therapies will likely leverage enhanced diffusion kinetics and targeted delivery for improved efficacy and safety.